saralasin and taprostene

saralasin has been researched along with taprostene* in 1 studies

Other Studies

1 other study(ies) available for saralasin and taprostene

ArticleYear
Role of renin release in the hemodynamic, renal and dipsogenic actions of the prostacyclin analogue CG 4203 in conscious rats.
    Prostaglandins, leukotrienes, and medicine, 1983, Volume: 11, Issue:4

    The influence of CG 4203, a chemically and metabolically stable prostacyclin analogue, on plasma renin activity, arterial blood pressure, renal function and water intake was investigated in conscious rats. CG 4203 infused intravenously starting at 1 microgram X kg-1 X min-1 induced both a fall in blood pressure and an increase of plasma renin activity. The angiotensin II antagonist saralasine infused simultaneously intensified the hypotensive effect of CG 4203 (1.0 microgram X kg-1 X min-1). Within a similar dose range CG 4203 dose-dependently inhibited diuresis and saluresis and reduced the urinary sodium/potassium ratio. These effects were partially reversed by adrenalectomy and completely abolished by pretreatment with the angiotensin I converting enzyme inhibitor captopril. Similarly, CG 4203 (0.21 - 4.64 micrograms X kg-1 X min-1) dose-dependently caused increased water intake which was prevented by previous nephrectomy. In conclusion, it is demonstrated that CG 4203 like prostacyclin itself already at hypotensive threshold dosages stimulates a functionally relevant renin release. The activation of the renin-angiotensin-aldosterone system attenuates the intrinsic hypotensive effects of CG 4203. the antidiuretic and dipsogenic efficacy of CG 4203 can also be attributed to renin-dependent angiotensin II formation.

    Topics: Adrenalectomy; Animals; Blood Pressure; Captopril; Diuresis; Drinking; Epoprostenol; Kidney; Male; Rats; Rats, Inbred Strains; Renin; Saralasin

1983